



Lee's Pharmaceutical Holdings Limited
李氏大藥廠控股有限公司

Approval received to initiate clinical study for Trittico®

[4 January 2011 - Hong Kong] **Lee's Pharmaceutical Holdings Limited** ("Lee's **Pharmaceutical**" or the "Group", Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China, today announced that the Group has just received approval from the State Food and Drug Administration of the People's Republic of China to initiate clinical study for its license-in product **Trittico®** (with active ingredient Trazodone Hydrochloride).

Trazodone, a potent postsynaptic serotonin 5-HT_{2A} receptor antagonist and a moderate inhibitor of serotonin reuptake, is the original member of the SARIs (serotonin-2 antagonist/reuptake inhibitors) group of antidepressants. The targeted indication is depression with or without anxiety, including sleep disorders in depressed patients. The product has been widely prescribed since its original launch in 1990's by its originator Angelini. Trittico® is a sustained release formulation newly developed by Angelini with better patient compliance.

According to the WHO, it is estimated that 5% to 10% of the population at any given time is suffering from identifiable depression and requires psychiatric treatment or psychosocial intervention. Despite the seriousness of depression as a disease and the availability of effective treatment, only 30% of cases worldwide receive appropriate care. As the general awareness of mental health continues to improve, we anticipate large unmet demand for the treatment of depression. It is estimated that the anti-depression market in China was US\$393.5 million in 2009.

"This is the sixth approval we have received in the last three years for clinical study in China. It is another milestone of our in-licensing efforts." said Dr. Benjamin Li, CEO of the Group. "Depression prevalence has been increased significantly in China during the last 20 years. With Trittico®, Lee's will be positioned itself as an important player in a fast growing depression market in China."

About Angelini

Angelini, a privately owned, international group with Italian roots, is leader in the healthcare and wellbeing market in the pharmaceutical and mass market sectors. Angelini was founded in Italy at the beginning of the 20th Century. Today, it is a medium-sized group with branches in 18 countries and worldwide product distribution. In the Pharmaceutical sector, Angelini focuses mainly on pain relief, inflammation, CNS, paediatrics, cold&flu, oralcare & sorethroat, gynecology, disinfection. Angelini is one of the top four pharmaceutical companies in Italy by sales volume. Guided by the President Francesco Angelini, the group employs about 3,500 people. In 2009 the consolidated turnover was over 1.2 billion Euros.

Information about Lee's Pharmaceutical Holdings Limited

Lee's Pharmaceutical Holdings Limited, a biopharmaceutical company, was successfully listed on the Main Board of the Stock Exchange of Hong Kong Limited in 2010, with over 15 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing and sales and marketing in China with global perspective and it currently markets nine products in China. The Group focuses on many different areas such as cardiovascular diseases, dermatology, oncology, gynecology and others with more than 22 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various US and European companies.

Disclaimer

Information presented in this press release is subject to change without notice, its accuracy is not guaranteed and it may not contain all material information concerning Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Company"). The Company makes no representation regarding, and assumes no responsibility or liability for, the accuracy or completeness of, or any errors or omissions in, any information contained herein. In addition, the information contains projections and forward-looking statements that may reflect the Company's current views with respect to future events and financial performance. These views are based on current assumptions which are subject to various risks and which may change over time. No assurance can be given that future events will occur, that projections will be achieved, or that the Company's assumptions are correct. It is not the intention to provide, and you may not rely on this presentation as providing, a complete or comprehensive analysis of the Company's financial or trading position or prospects.